Soleno Therapeutics (SLNO) Receivables - Other (2013 - 2019)

Soleno Therapeutics' (SLNO) quarterly Receivables - Other came in at $9000.0 in Q3 2019, down 50.0% on a QoQ basis from $18000.0 in Q2 2019.

Soleno Therapeutics (SLNO) Receivables - Other (2013 - 2019) Analysis & Trends

Soleno Therapeutics (SLNO) has 4 years of Receivables - Other data on file, last reported at $9000.0 in Q3 2019.

On a quarterly basis, Receivables - Other changed N/A year-over-year to $9000.0 in Q3 2019; TTM through Sep 2019 was $9000.0, a N/A change from a year earlier, with the FY2018 full-year figure at $64000.0, changed N/A from the prior year.
Receivables - Other for Q3 2019 stood at $9000.0, down from $18000.0 in the prior quarter.
Over the last five years, Receivables - Other for SLNO reached as high as $72000.0 in Q1 2019 and fell as low as $9000.0 in Q3 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Soleno Therapeutics	874.25 Mn	618.67 Mn	93.41 Mn

Download Data